Triton’s research on the Europe immunosuppressants drugs market depicts that it will grow at a stable pace with a CAGR of 5.94% in terms of revenue during the forecast period 2019-2028.
The countries evaluated in this market include:
• The UK
• Germany
• France
• Spain
• Italy
• Russia
• Rest of Europe
Over 80 different types of autoimmune diseases are prevalent in the United Kingdom, affecting more than 4 million people. While advancements in technology have enabled the formulation of treatments to reduce autoimmune attacks, these diseases still have no cure. Existing drugs may not show effectiveness when given to all patients, and may even result in side-effects. It is necessary to have a better knowledge of how these diseases develop, so as to develop better treatments.
In the past couple of years, many investigations involving the genetics of autoimmunity have discovered a common feature - a particular gene named TYK2. This gene is also associated with multiple other autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, lupus, and type 1 diabetes. After discovering this gene, a drug targeting TYK2 was developed, and it seems promising for the treatment of psoriasis. In fact, looking at the positive results, this drug generates hope for the treatment of other autoimmunity-related conditions as well. However, these are future developments, and, till then, immunosuppressants drugs will be in huge demand for the treatment of autoimmune diseases.
In France, all citizens automatically become organ donors, unless they decide to opt-out. This comes after the amendment in laws pertaining to organ donation. This law is now in line with similar laws enacted in Austria and Spain, where there is “presumed consent.” This means, every person is eligible for donating organs and tissues after death, unless they specifically decide not to. Thus, there is a huge demand for organ transplantation in the country. The growing demand for organ transplantation implies an increase in the demand for immunosuppressant drugs. This is helping the growth of the immunosuppressant drugs market in the country over the forecasted period.
Allergan (acquired by AbbVie Inc), is a global specialty pharma company focused on developing, manufacturing, selling, marketing, and distributing pharmaceutical products, medical aesthetics, biosimilars and OTC pharmaceutical products. Restasis and Restasis MultidoseTM are the immunosuppressant drugs manufactured by the company. It is headquartered in Dublin, Ireland.
The top key players in the immunosuppressant drugs market are Pfizer Inc, Janssen Pharmaceuticals Inc (Johnson & Johnson Services Inc), Veloxis Pharmaceuticals Inc, Intas Pharmaceuticals Ltd (Accord Healthcare), Dr Reddys Laboratories Ltd, Cipla Ltd, GlaxoSmithKline plc, F Hoffmann-La Roche Ltd, Mylan NV, Novartis AG, Astellas Pharma Inc, Allergan (acquired by Abbvie Inc), Abbvie Inc, Bristol-Myers Squibb Company, and Sanofi.